On September 20, 2021 Azurity Pharmaceuticals, Inc. ("Azurity") reported the closing of its acquisition of Arbor Pharmaceuticals, Inc. ("Arbor"), as previously announced on August 24, 2021 (Press release, Arbor Pharmaceuticals, SEP 20, 2021, View Source [SID1234590054]). The acquisition creates a leading company offering innovative, high-value products to meet the unique needs of patients with underserved conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

With this acquisition, Arbor is now a wholly-owned subsidiary of Azurity. The two companies will begin to integrate their operations over the coming months and will operate as Azurity post-integration.